Status | Study |
No longer available |
Study Name: Treatment With Crizotinib Single Patient Expanded Access IND 134375 Condition: Inflammatory Myofibroblastic Tumour Date: 2017-03-14 Interventions: Drug: Crizotinib |
Enrolling by invitation |
Study Name: Low-dose Protocol for Computed Tomography-guided Lung Biopsy Condition: Lung Cancer, Adenocarcinoma Lung Inflammatory Pseudotumor Date: 2016-11-17 Interventions: Radiation: Low-dose protocol computed tomography |
Recruiting |
Study Name: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Condition: Adult Fibrosarcoma Alveolar Soft Part Sarcoma Angiomatoid Date: 2014-07-01 Interventions: Drug: Doxorubicin Hydrochloride |
Recruiting |
Study Name: CREATE: Cross-tumoral Phase 2 With Crizotinib Condition: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma Locally Advanced and/or Me Date: 2012-01-24 Interventions: Drug: Crizotinib (PF-02341066) For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of |
Recruiting |
Study Name: A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Condition: Advanced Malignancies Carcinoma, Non-Small-Cell Lung Anapl Date: 2011-09-30 Interventions: Drug: AP26113 30 mg tablet(s) taken orally and increasing in increments until the maximum tolerated dose |